Related Experiment Video
Updated: Oct 19, 2026

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
Published on: May 22, 2026
Management of pulmonary tuberculosis PTB: regimen employed in Lagos, Nigeria
1Tuberculosis Unit, Nigerian Institute of Medical Research, Yaba-Lagos, Nigeria.
Abstract:
The regimen(s) employed for the management of pulmonary tuberculosis (PTB) by health institutions in Lagos State, Nigeria was determined. Results from the 134 health institutions, showed that only 71.7% of the 120 (89.6%) health institutions with records of PTB, manage these cases. 28.3% refer diagnosed cases to referral (chest) centres. 4.7% administered multiple regimen and 93.0%, single regimen of different drug combinations for different treatment periods/durations. The study showed that 36.9% of the health institutions in Lagos employed a short course chemotherapy (SCC) treatment of between 6 to 9 months duration, while 32.2% employ the longer course of chemotherapy with duration of treatment not less than 10 months. Majority, employed the SCC regimen of 6 months duration using 2SRHZ/4RH combination. Most of the institutions employed a regimen outside the national adopted 8 months regimen that consist of four drugs: streptomycin (S), or ethambutol (E), rifampicin (R), isoniazid (H), and pyrazinamide (Z) for the first two months of intensive treatment and two drugs of isoniazid (H) and thiacetazone (T), for the final continuation phase of six months. (i.e. a regimen of 2S or ERHZ/6TH). The overall results, showed there is no commonly accepted PTB treatment regimen in Lagos and the national adopted regimen is not favoured by many health institutions. There is the need for the development of a standard, generally accepted, affordable and cost effective treatment regimen for the state and country, for effective monitoring and coordination.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis